NL301199I2 - Difelikefalin, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, hydraat, solvaat, zuurzout-hydraat of N-oxide - Google Patents

Difelikefalin, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, hydraat, solvaat, zuurzout-hydraat of N-oxide

Info

Publication number
NL301199I2
NL301199I2 NL301199C NL301199C NL301199I2 NL 301199 I2 NL301199 I2 NL 301199I2 NL 301199 C NL301199 C NL 301199C NL 301199 C NL301199 C NL 301199C NL 301199 I2 NL301199 I2 NL 301199I2
Authority
NL
Netherlands
Prior art keywords
hydrate
difelikefalin
solvate
optionally
oxide
Prior art date
Application number
NL301199C
Other languages
English (en)
Other versions
NL301199I1 (nl
Original Assignee
Cara Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39284138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL301199(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cara Therapeutics Inc filed Critical Cara Therapeutics Inc
Publication of NL301199I1 publication Critical patent/NL301199I1/nl
Publication of NL301199I2 publication Critical patent/NL301199I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
NL301199C 2006-11-10 2022-10-12 Difelikefalin, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, hydraat, solvaat, zuurzout-hydraat of N-oxide NL301199I2 (nl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85810906P 2006-11-10 2006-11-10
US92855007P 2007-05-10 2007-05-10
PCT/US2007/023858 WO2008057608A2 (en) 2006-11-10 2007-11-12 Synthetic peptide amides

Publications (2)

Publication Number Publication Date
NL301199I1 NL301199I1 (nl) 2022-10-19
NL301199I2 true NL301199I2 (nl) 2023-02-16

Family

ID=39284138

Family Applications (1)

Application Number Title Priority Date Filing Date
NL301199C NL301199I2 (nl) 2006-11-10 2022-10-12 Difelikefalin, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, hydraat, solvaat, zuurzout-hydraat of N-oxide

Country Status (26)

Country Link
US (7) US7402564B1 (nl)
EP (1) EP2064228B1 (nl)
JP (1) JP5244810B2 (nl)
KR (1) KR101513736B1 (nl)
CN (1) CN101627049B (nl)
AU (1) AU2007317817B2 (nl)
BR (1) BRPI0718651B8 (nl)
CA (1) CA2667155C (nl)
CY (2) CY1116760T1 (nl)
DK (1) DK2064228T3 (nl)
ES (1) ES2394377T3 (nl)
FI (1) FIC20220043I1 (nl)
FR (1) FR22C1054I2 (nl)
HU (1) HUS2200045I1 (nl)
IL (1) IL197923A (nl)
LT (1) LTC2064228I2 (nl)
LU (1) LUC00282I2 (nl)
MX (1) MX2009005000A (nl)
MY (1) MY148144A (nl)
NL (1) NL301199I2 (nl)
NZ (1) NZ577107A (nl)
PL (1) PL2064228T3 (nl)
PT (1) PT2064228E (nl)
RU (1) RU2500685C2 (nl)
WO (1) WO2008057608A2 (nl)
ZA (1) ZA200903054B (nl)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US6923175B2 (en) 2002-03-20 2005-08-02 Mannkind Corporation Inhalation apparatus
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
KR20130066695A (ko) 2004-08-23 2013-06-20 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
EP1986679B1 (en) 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
CN101454338A (zh) * 2006-05-26 2009-06-10 卡拉治疗学股份有限公司 κ阿片样受体肽的N-氧化物
US8236766B2 (en) * 2006-11-10 2012-08-07 Cara Therapeutics, Inc. Uses of synthetic peptide amides
US7713937B2 (en) * 2006-11-10 2010-05-11 Cara Therapeutics, Inc. Synthetic peptide amides and dimeric forms thereof
US20170007574A1 (en) * 2015-07-02 2017-01-12 Cara Therapeutics, Inc. Peripheral kappa opioid receptor agonists for uremic pruritus in dialysis patients
MX2009005000A (es) * 2006-11-10 2009-10-12 Cara Therapeutics Inc Amidas de peptidos sinteticos.
US7842662B2 (en) 2006-11-10 2010-11-30 Cara Therapeutics, Inc. Synthetic peptide amide dimers
US8906859B2 (en) 2006-11-10 2014-12-09 Cera Therapeutics, Inc. Uses of kappa opioid synthetic peptide amides
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CN101827626B (zh) 2008-06-13 2015-03-18 曼金德公司 干粉吸入器和用于药物输送的系统
ES2421385T3 (es) 2008-06-20 2013-09-02 Mannkind Corp Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
US8809278B2 (en) 2008-07-11 2014-08-19 University Of Kansas Cyclic tetrapeptides
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
WO2010037081A1 (en) 2008-09-29 2010-04-01 Palatin Technologies, Inc. Melanocortin receptor-specific spiro-piperidine compounds
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
DK2405963T3 (da) 2009-03-11 2013-12-16 Mannkind Corp Apparat, system og fremgangsmåde til at måle modstand i en inhalator
KR102584844B1 (ko) 2009-06-12 2023-10-04 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
KR20120118008A (ko) * 2009-12-18 2012-10-25 아이데닉스 파마슈티칼스, 인코포레이티드 5,5-융합 아릴렌 또는 헤테로아릴렌 간염 ｃ 바이러스 억제제
CN102985125A (zh) 2010-06-21 2013-03-20 曼金德公司 干粉药物输送系统和方法
DE102010062810B4 (de) * 2010-09-07 2014-03-13 Immungenetics Ag 2-(R2-Thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine zur Behandlung neurodegenerativer Erkrankungen ausgewählt aus beta-Amyloidopathien und alpha-Synucleinopathien
SG194034A1 (en) 2011-04-01 2013-11-29 Mannkind Corp Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
MX2014004983A (es) 2011-10-24 2014-09-22 Mannkid Corp Metodos y composiciones para tratar dolor.
US20150150935A1 (en) * 2012-06-05 2015-06-04 Cara Therapeutics, Inc. Peripheral kappa receptor agonists for reducing pain and inflammation
KR102264177B1 (ko) 2012-07-12 2021-06-11 맨카인드 코포레이션 건조 분말 약물 전달 시스템 및 방법
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
EP3587404B1 (en) 2013-03-15 2022-07-13 MannKind Corporation Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
MX375448B (es) 2013-07-18 2025-03-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
CA2953653C (en) * 2014-06-26 2021-02-16 Maruishi Pharmaceutical Co., Ltd. Method for producing synthetic pentapeptide
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
WO2016064873A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US10550150B2 (en) 2015-05-11 2020-02-04 Cadila Healthcare Limited Short-chain peptides as Kappa (κ) opioid receptors (KOR) agonist
WO2017120468A1 (en) * 2016-01-06 2017-07-13 Trevi Therapeutics, Inc. Therapeutic use of nalbuphine without aquaretic effects
CN107098871B (zh) * 2016-02-23 2021-07-02 江苏恒瑞医药股份有限公司 苯基丙酰胺类衍生物、其制备方法及其在医药上的应用
US20200316159A1 (en) * 2016-06-03 2020-10-08 Jt Pharmaceuticals, Inc. Sustained release compositions of kappa-opioid receptor agonist
AU2017277003B2 (en) * 2016-06-07 2021-01-07 Jiangsu Hengrui Medicine Co., Ltd. Phenyl propanamide derivative, and manufacturing method and pharmaceutical application thereof
US11084847B2 (en) 2016-09-27 2021-08-10 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Polyamide compound and use thereof
WO2018103624A1 (zh) * 2016-12-06 2018-06-14 江苏恒瑞医药股份有限公司 一种κ阿片受体激动剂在制备治疗法尼醇X受体激动剂引起的瘙痒的药物中的用途
ES2747768T3 (es) 2017-03-20 2020-03-11 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR)
WO2018191450A2 (en) 2017-04-14 2018-10-18 National Taiwan University Hospital Gene therapy for aadc deficiency
CA3058272A1 (en) * 2017-04-14 2018-10-18 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing mor agonist and kor agonist, and uses thereof
CN109280076B (zh) * 2017-07-21 2022-04-05 四川海思科制药有限公司 肽酰胺类化合物及其制备方法和在医药上的用途
CN109280075B (zh) * 2017-07-21 2022-05-20 四川海思科制药有限公司 肽酰胺类化合物及其制备方法和在医药上的用途
EP3656782B1 (en) * 2017-07-21 2021-12-22 Sichuan Haisco Pharmaceutical Co., Ltd. Peptide amide compound and preparation method and medical use thereof
JP2021505547A (ja) * 2017-12-06 2021-02-18 江蘇恒瑞医薬股▲ふん▼有限公司 疼痛を治療するための薬物の製造におけるｍｏｒアゴニストと組み合わせたｋｏｒアゴニストの使用
CA3084201A1 (en) * 2017-12-06 2019-06-13 Jiangsu Hengrul Medicine Co., Ltd. Salt of phenylpropionamide derivative and preparation method therefor
WO2019134510A1 (zh) * 2018-01-03 2019-07-11 四川科伦博泰生物医药股份有限公司 短肽季铵盐化合物及其用途
WO2019154151A1 (zh) * 2018-02-12 2019-08-15 四川科伦博泰生物医药股份有限公司 一种中间体化合物及其制备方法，及以该中间体化合物制备多肽的固相合成方法
US20230097887A1 (en) 2018-04-09 2023-03-30 Yale University Bi-functional Molecules to Degrade Circulating Proteins
US12485178B2 (en) 2018-04-09 2025-12-02 Yale University Bifunctional small molecules to target the selective degradation of circulating proteins
US12364766B2 (en) 2018-04-09 2025-07-22 Yale University Bifunctional small molecules to target the selective degradation of circulating proteins
WO2019199621A1 (en) 2018-04-09 2019-10-17 Yale University Bi-functional molecules to degrade circulating proteins
CN108653288B (zh) * 2018-05-29 2020-05-05 福建医科大学孟超肝胆医院(福州市传染病医院) 一种乏氧响应聚合物纳米粒及其应用
JP2021531299A (ja) 2018-07-23 2021-11-18 トレビ セラピューティクス インコーポレイテッド 慢性咳嗽、息切れ、及び呼吸困難の治療
IL281393B2 (en) * 2018-09-14 2025-02-01 Cara Therapeutics Inc Oral formulations of kappa opioid receptor agonists
ES2989438T3 (es) 2018-09-19 2024-11-26 Novo Nordisk Healthcare Ag Activación de la piruvato cinasa R
US12053458B2 (en) 2018-09-19 2024-08-06 Novo Nordisk Health Care Ag Treating sickle cell disease with a pyruvate kinase R activating compound
CN113301925A (zh) 2018-12-19 2021-08-24 小利兰·斯坦福大学理事会 用于溶酶体靶向的双官能分子以及相关的组合物和方法
CN114127085B (zh) * 2019-07-25 2024-08-13 西藏海思科制药有限公司 一种肽酰胺盐及其制备方法和在医药上的用途
CN114127086B (zh) * 2019-07-25 2023-10-20 四川海思科制药有限公司 氘代肽酰胺类化合物及其制备方法和在医药上的用途
US12215173B2 (en) 2019-08-07 2025-02-04 HUMANWELL PHARMACEUTICAL US, Inc. Kappa opioid receptor peptide amide ligands
TWI764248B (zh) * 2019-08-23 2022-05-11 大陸商四川海思科製藥有限公司 肽醯胺類組合物及其製備
US20220378756A1 (en) 2019-09-19 2022-12-01 Forma Therapeutics, Inc. Activating pyruvate kinase r
MX2022004342A (es) * 2019-10-10 2022-07-19 Univ Yale Degradadores bifuncionales dirigidos.
KR20220127849A (ko) 2020-01-10 2022-09-20 트레비 테라퓨틱스, 인코포레이티드 날부핀의 투여 방법
EP4122483B1 (en) * 2020-03-18 2025-04-30 Xizang Haisco Pharmaceutical Co., Ltd. Oral pharmaceutical composition
CA3171225A1 (en) * 2020-03-18 2021-09-23 Bryan R. Wilson Oligosaccharide formulations of kappa opioid receptor agonists
CN113493490B (zh) * 2020-04-03 2024-03-12 成都诺和晟泰生物科技有限公司 一种合成肽酰胺类化合物及其在医药领域的用途
JP7549439B2 (ja) 2020-04-30 2024-09-11 メッドシャイン ディスカバリー インコーポレイテッド フェニルプロピオンアミド系化合物及びその使用
KR20230024419A (ko) 2020-06-25 2023-02-20 휴먼웰 파마슈티컬 유에스 의학적 장애 치료용 펩티드
US12109327B2 (en) 2020-08-20 2024-10-08 King Abdullah University Of Science And Technology Scaffolds from self-assembling tetrapeptides support 3D spreading, osteogenic differentiation and angiogenesis of mesenchymal stem cells
US12590121B2 (en) * 2020-08-20 2026-03-31 King Abdullah University Of Science And Technology Peptide compound with repetitive sequences
US12116421B2 (en) 2020-09-02 2024-10-15 King Abdullah University Of Science And Technology Peptide-based Dopa containing adhesive gels
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
MX2023012087A (es) * 2021-04-14 2024-02-27 Titan Pharmaceuticals Inc Implantes de agonistas de los receptores kappa-opioides para tratamiento del prurito.
WO2022225045A1 (ja) * 2021-04-23 2022-10-27 東レ株式会社 グレリン抵抗性を伴う悪液質の治療剤又は予防剤
AU2022310356A1 (en) 2021-07-14 2024-01-25 Lycia Therapeutics, Inc. Asgpr cell surface receptor binding compounds and conjugates
CN113461775A (zh) * 2021-08-23 2021-10-01 成都诺和晟泰生物科技有限公司 一种多肽化合物的制备方法
US20230285497A1 (en) * 2022-03-11 2023-09-14 Cara Therapeutics, Inc. Atopic dermatitis therapy with kappa opioid receptor agonist as adjunct to topical corticosteroid
CN118891270A (zh) 2022-03-23 2024-11-01 江苏恩华药业股份有限公司 多酰胺类化合物、其制备方法及其医药用途
KR102810165B1 (ko) * 2022-03-31 2025-05-22 (주)케어젠 항염증 및 항섬유화 활성을 갖는 펩타이드 및 이의 용도
CN119836295A (zh) * 2022-07-11 2025-04-15 人福医药美国公司 用于治疗医学病症的肽
AU2023396555A1 (en) * 2022-12-15 2025-07-10 Yichang Humanwell Pharmaceutical Co., Ltd. Pharmaceutical composition of kappa opioid receptor agonist, preparation method therefor, and use thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3619633A1 (de) 1986-06-11 1987-12-17 Hoechst Ag Peptide mit einfluss auf die diurese und natriurese, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
AU1711888A (en) 1987-04-24 1988-12-02 Biogen, Inc. Immunotherapeutic methods and compositions
EP0334244A3 (en) 1988-03-25 1991-05-29 The Procter & Gamble Company Bradykinin antagonist peptides
NZ229004A (en) 1988-05-19 1993-09-27 Immunobiology Res Inst Inc Tetrapeptides having t cell helper acitivity
FI902534A7 (fi) 1988-09-30 1990-05-22 Immunobiology Res Institute Inc Peptidejä, joilla on T-solusuppressoriaktiivisuutta
HU207104B (en) 1991-01-25 1993-03-01 Biosignal Kutato Fejlesztoe Kf Process for producing new somatostatin analogs inhibiting tumour growth and pharmaceutical compositions comprising such compounds
JP2745351B2 (ja) 1991-02-14 1998-04-28 富士写真フイルム株式会社 ペプチド誘導体及びその用途
FR2677361A1 (fr) 1991-06-04 1992-12-11 Adir Nouveaux peptides et pseudopeptides, derives de tachykinines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5403824A (en) 1993-03-19 1995-04-04 The Procter & Gamble Company Methods for the treatment of osteoporosis
DE4310643A1 (de) 1993-04-01 1994-10-06 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
EP0679658A4 (en) 1993-06-25 1997-06-04 Kyowa Hakko Kogyo Kk Endothelin-antagonizing peptide.
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
SE9503924D0 (sv) 1995-08-18 1995-11-07 Astra Ab Novel opioid peptides
RU2067000C1 (ru) 1994-06-29 1996-09-27 Владислав Исакович Дейгин Пептид и способ его получения
US5888978A (en) 1995-09-12 1999-03-30 Trega Biosciences, Inc. Method for reducing the severity of gastro-intestinal damage
PT929574E (pt) 1996-08-27 2005-11-30 Praecis Pharm Inc Moduladores da agregacao de peptidos beta-amiloides compreendendo d-aminoacidos
AU3938797A (en) 1996-08-29 1998-03-19 Novo Nordisk A/S Transdermal delivery of peptides
CA2224066A1 (en) 1997-10-24 1999-04-24 Universite D'ottawa/ University Of Ottawa Peptides as analgesics
US6191103B1 (en) 1997-12-05 2001-02-20 The Regents Of The University Of California Methods for enhancing thrombolysis in a mammal
US5965701A (en) * 1997-12-23 1999-10-12 Ferring Bv Kappa receptor opioid peptides
JP2002512368A (ja) 1998-04-23 2002-04-23 カロ バイオ ユー エス エイ，インコーポレイテッド 受容体の生物活性を調節するための化合物の能力を予測する方法
US6984719B1 (en) 1998-09-17 2006-01-10 Hospital Sainte-Justine Peptide antagonists of prostaglandin F2α receptor
US6780846B1 (en) 1999-09-27 2004-08-24 Elan Corporation, Plc Membrane translocating peptide drug delivery system
WO2001036006A1 (en) 1999-11-19 2001-05-25 Palatin Technologies, Inc. Opioid metallopeptide compositions and methods
US7348162B2 (en) 2000-03-22 2008-03-25 Amgen Inc. Nucleic acids encoding fibroblast growth factor receptor-like proteins and uses thereof
US20030050246A1 (en) 2001-07-26 2003-03-13 Fortuna Haviv Peptides having antiangiogenic activity
WO2003048323A2 (en) 2001-12-03 2003-06-12 Bristol-Myers Squibb Company Polynucleotides and polypeptides associated with the development of rheumatoid arthritis
US20050113294A1 (en) 2003-11-21 2005-05-26 Adolor Corporation. Carboxamide and amino derivatives and methods of their use
JP2008521840A (ja) 2004-11-30 2008-06-26 ガストロテック・ファルマ・アクティーゼルスカブ 成長ホルモン分泌促進物質レセプター１ａリガンド
CN101155825B (zh) 2005-02-09 2014-11-26 赫里克斯生物医疗公司 抗微生物六肽
US8906859B2 (en) * 2006-11-10 2014-12-09 Cera Therapeutics, Inc. Uses of kappa opioid synthetic peptide amides
US7713937B2 (en) * 2006-11-10 2010-05-11 Cara Therapeutics, Inc. Synthetic peptide amides and dimeric forms thereof
US8236766B2 (en) * 2006-11-10 2012-08-07 Cara Therapeutics, Inc. Uses of synthetic peptide amides
US7842662B2 (en) * 2006-11-10 2010-11-30 Cara Therapeutics, Inc. Synthetic peptide amide dimers
MX2009005000A (es) * 2006-11-10 2009-10-12 Cara Therapeutics Inc Amidas de peptidos sinteticos.

Also Published As

Publication number Publication date
MY148144A (en) 2013-03-15
JP2010509343A (ja) 2010-03-25
US10793596B2 (en) 2020-10-06
BRPI0718651B1 (pt) 2020-06-02
US7727963B2 (en) 2010-06-01
CA2667155C (en) 2016-05-10
CA2667155A1 (en) 2008-05-15
BRPI0718651A2 (pt) 2013-11-19
US20160362450A1 (en) 2016-12-15
FR22C1054I1 (fr) 2022-12-16
PT2064228E (pt) 2012-12-10
DK2064228T3 (da) 2012-12-10
FR22C1054I2 (fr) 2023-10-13
US8951970B2 (en) 2015-02-10
HUS2200045I1 (hu) 2022-11-28
WO2008057608A8 (en) 2008-12-11
NZ577107A (en) 2012-01-12
CY2022032I1 (el) 2023-01-05
WO2008057608A2 (en) 2008-05-15
HK1130814A1 (en) 2010-01-08
NL301199I1 (nl) 2022-10-19
BRPI0718651B8 (pt) 2021-05-25
RU2500685C2 (ru) 2013-12-10
FIC20220043I1 (fi) 2022-10-20
LTC2064228I2 (nl) 2025-03-10
CY2022032I2 (el) 2023-06-09
CN101627049B (zh) 2012-09-05
US9359399B2 (en) 2016-06-07
ZA200903054B (en) 2010-02-24
KR20090085096A (ko) 2009-08-06
RU2009121297A (ru) 2010-12-20
MX2009005000A (es) 2009-10-12
LUC00282I2 (nl) 2024-10-04
CY1116760T1 (el) 2017-03-15
AU2007317817A1 (en) 2008-05-15
EP2064228A2 (en) 2009-06-03
US7402564B1 (en) 2008-07-22
AU2007317817B2 (en) 2012-09-20
KR101513736B1 (ko) 2015-04-20
US8217007B1 (en) 2012-07-10
US20130012448A1 (en) 2013-01-10
US20090075907A1 (en) 2009-03-19
US10138270B2 (en) 2018-11-27
ES2394377T3 (es) 2013-01-31
WO2008057608A3 (en) 2009-09-24
LTPA2022522I1 (nl) 2022-11-10
JP5244810B2 (ja) 2013-07-24
EP2064228B1 (en) 2012-08-29
US20190241610A1 (en) 2019-08-08
US20150197545A1 (en) 2015-07-16
PL2064228T3 (pl) 2013-01-31
IL197923A0 (en) 2009-12-24
IL197923A (en) 2016-06-30
CN101627049A (zh) 2010-01-13

Similar Documents

Publication Publication Date Title
NL301199I2 (nl) Difelikefalin, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, hydraat, solvaat, zuurzout-hydraat of N-oxide
NL301067I2 (nl) Cefiderocol, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat
NL301299I2 (nl) Capivasertib, eventueel in de vorm van een farmaceutisch aanvaardbaar zout
NL301321I2 (nl) Delgocitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat daarvan
NL301150I2 (nl) setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301049I1 (nl) Crisaborale, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301033I2 (nl) Larotrectinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder larotrectinibsulfaat, met inbegrip van larotrectinibsulfaat monohydraat
NL301057I1 (nl) Glasdegib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, met inbegrip van het maleaatzout
NL301042I1 (nl) Trifaroteen, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301021I1 (nl) talazoparib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout.
NL301261I2 (nl) Gefapixant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout.
NL301004I2 (nl) Dacomitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301041I2 (nl) Darolutamide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout daarvan of in de vorm van een farmaceutisch aanvaardbare ester daarvan
NL301104I1 (nl) Fedratinib, of een farmaceutisch aanvaardbaar zout daarvan, of een farmaceutisch aanvaardbaar hydraat daarvan, in het bijzonder fedratinibdihydrochloridemonohydraat
NL300909I2 (nl) Ribociclib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL350110I2 (nl) Oxathiapiproline, desgewenst in de vorm van het N-oxide ervan of een zout ervan, en amisulbrom
NL300937I2 (nl) Niraparib, of een tautomeer daarvan, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder het tosylaat of een hydraat, meer in het bijzonder het tosylaat monohydraat
NL301065I2 (nl) Ozanimod of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder ozanimodhydrochloride
NL301256I2 (nl) cedazuridine, of een farmaceutisch aanvaardbaar zout daarvan
NL301209I2 (nl) capmatinib of een farmaceutisch aanvaardbaar zout daarvan
NL300946I2 (nl) Brexpiprazole, desgewenst in de vorm van een zout
NL301230I2 (nl) Mitapivat, dan wel een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder mitapivatsulfaat
NL301305I2 (nl) Vibegron of een farmaceutisch aanvaardbaar zout daarvan
NL301047I2 (nl) fosnetupitant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder fosnetupitantchloridehydrochloride
NL301166I2 (nl) Avacopan of een farmaceutisch aanvaardbaar zout daarvan